Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice

AimsOligoprogression is poorly defined in current literature. Little is known about the natural history and significance of oligoprogression in patients with hormone-resistant prostate cancer on abiraterone or enzalutamide treatment [termed androgen receptor-targeted therapy (ARTT)]. The aim of this...

Full description

Bibliographic Details
Main Authors: Priyanka H. Patel, Nina Tunariu, Daniel S. Levine, Johann S. de Bono, Rosalind A. Eeles, Vincent Khoo, Julia Murray, Christopher C. Parker, Angela Pathmanathan, Alison Reid, Nicholas van As, Alison C. Tree
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Oncology
Subjects:
oligoprogression
stereotactic body radiotherapy
castrate resistant prostate cancer
abiraterone
enzalutamide
Androgen receptor targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.862995/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.862995/full

Similar Items